QQQ   353.65 (-0.16%)
AAPL   170.16 (-1.05%)
MSFT   311.72 (-0.13%)
META   299.74 (+0.26%)
GOOGL   129.83 (+0.98%)
AMZN   124.87 (-0.88%)
TSLA   237.34 (-2.78%)
NVDA   419.09 (+0.00%)
NIO   8.35 (-0.71%)
BABA   85.71 (-0.23%)
AMD   97.62 (+1.73%)
T   14.80 (-1.46%)
F   12.32 (-0.88%)
MU   67.27 (-0.99%)
CGC   0.87 (-5.79%)
GE   111.18 (+1.14%)
DIS   79.36 (-0.86%)
AMC   7.80 (-1.39%)
PFE   32.02 (-1.17%)
PYPL   57.18 (-2.97%)
NFLX   378.79 (-0.12%)
QQQ   353.65 (-0.16%)
AAPL   170.16 (-1.05%)
MSFT   311.72 (-0.13%)
META   299.74 (+0.26%)
GOOGL   129.83 (+0.98%)
AMZN   124.87 (-0.88%)
TSLA   237.34 (-2.78%)
NVDA   419.09 (+0.00%)
NIO   8.35 (-0.71%)
BABA   85.71 (-0.23%)
AMD   97.62 (+1.73%)
T   14.80 (-1.46%)
F   12.32 (-0.88%)
MU   67.27 (-0.99%)
CGC   0.87 (-5.79%)
GE   111.18 (+1.14%)
DIS   79.36 (-0.86%)
AMC   7.80 (-1.39%)
PFE   32.02 (-1.17%)
PYPL   57.18 (-2.97%)
NFLX   378.79 (-0.12%)
QQQ   353.65 (-0.16%)
AAPL   170.16 (-1.05%)
MSFT   311.72 (-0.13%)
META   299.74 (+0.26%)
GOOGL   129.83 (+0.98%)
AMZN   124.87 (-0.88%)
TSLA   237.34 (-2.78%)
NVDA   419.09 (+0.00%)
NIO   8.35 (-0.71%)
BABA   85.71 (-0.23%)
AMD   97.62 (+1.73%)
T   14.80 (-1.46%)
F   12.32 (-0.88%)
MU   67.27 (-0.99%)
CGC   0.87 (-5.79%)
GE   111.18 (+1.14%)
DIS   79.36 (-0.86%)
AMC   7.80 (-1.39%)
PFE   32.02 (-1.17%)
PYPL   57.18 (-2.97%)
NFLX   378.79 (-0.12%)
QQQ   353.65 (-0.16%)
AAPL   170.16 (-1.05%)
MSFT   311.72 (-0.13%)
META   299.74 (+0.26%)
GOOGL   129.83 (+0.98%)
AMZN   124.87 (-0.88%)
TSLA   237.34 (-2.78%)
NVDA   419.09 (+0.00%)
NIO   8.35 (-0.71%)
BABA   85.71 (-0.23%)
AMD   97.62 (+1.73%)
T   14.80 (-1.46%)
F   12.32 (-0.88%)
MU   67.27 (-0.99%)
CGC   0.87 (-5.79%)
GE   111.18 (+1.14%)
DIS   79.36 (-0.86%)
AMC   7.80 (-1.39%)
PFE   32.02 (-1.17%)
PYPL   57.18 (-2.97%)
NFLX   378.79 (-0.12%)
NASDAQ:AYLA

Ayala Pharmaceuticals (AYLA) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.44
▼
$0.57
50-Day Range
$0.38
▼
$0.58
52-Week Range
$0.36
▼
$7.31
Volume
137,700 shs
Average Volume
76,300 shs
Market Capitalization
$7.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsEarningsFinancialsInstitutional OwnershipSEC FilingsShort InterestSocial Media

AYLA stock logo

About Ayala Pharmaceuticals (NASDAQ:AYLA) Stock

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.


AYLA Stock News Headlines

January 19, 2023 | finanznachrichten.de
Advaxis, Inc.: Advaxis and Ayala Pharmaceuticals Complete Merger
January 19, 2023 | bizjournals.com
Cancer treatment developers Ayala Pharmaceuticals and Advaxis complete merger
September 27, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
November 17, 2022 | finance.yahoo.com
Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
November 16, 2022 | finance.yahoo.com
Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors
November 16, 2022 | finance.yahoo.com
Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors
November 4, 2022 | msn.com
Recap: Ayala Pharmaceuticals Q3 Earnings
November 4, 2022 | finance.yahoo.com
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
September 27, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
November 4, 2022 | finance.yahoo.com
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Lags Revenue Estimates
October 20, 2022 | markets.businessinsider.com
AutoZone To Rise Over 9%? Plus Roth Capital Slashes PT On This Stock By 96%
October 19, 2022 | msn.com
Why United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday's Mid-Day Session
October 19, 2022 | baystreet.ca
Ayala, Advaxis Merge
October 19, 2022 | markets.businessinsider.com
Ayala Pharma, Advaxis Announce Merger - Quick Facts
October 19, 2022 | bizjournals.com
Cancer treatment developers Ayala Pharmaceuticals and Advaxis to merge
September 30, 2022 | bizjournals.com
Lab Notes: 4 early stage life sciences firms close financing deals; 2 drug candidates get Fast Track approval
September 29, 2022 | finance.yahoo.com
Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors
September 27, 2022 | finance.yahoo.com
Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors
August 24, 2022 | finance.yahoo.com
Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 Congress
August 2, 2022 | bizjournals.com
Philadelphia-area life sciences companies with the largest stock, market cap declines in first half of 2022
July 27, 2022 | nasdaq.com
Ayala Pharmaceuticals Stock Nearly Triples on Twitter Post. Is it a Buy?
July 26, 2022 | nasdaq.com
Ayala Pharmaceuticals Stock Nearly Triples on Desmoid Tumor Treatment News
July 6, 2022 | finance.yahoo.com
HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging
July 5, 2022 | finance.yahoo.com
Ayala's Cancer Candidate Shrinks Tumor In Substantially All Patients In Late-Stage Study
June 2, 2022 | finance.yahoo.com
Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference
May 17, 2022 | nasdaq.com
Ayala Pharma To Report Phase II/III Study Of AL102 In Desmoid Tumors Around Mid-2022
May 16, 2022 | finance.yahoo.com
Ayala Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
See More Headlines
Receive AYLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AYLA Company Calendar

Last Earnings
11/15/2021
Today
9/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AYLA
CUSIP
N/A
CIK
1797336
Web
www.ayalapharma.com
Phone
857-444-0553
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.52)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-40,250,000.00
Net Margins
-2,341.69%
Pretax Margin
-2,298.60%
Return on Equity
-182.13%
Return on Assets
-139.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.28
Quick Ratio
2.28

Sales & Book Value

Annual Sales
$3.51 million
Price / Sales
2.13
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.45 per share
Price / Book
0.21

Miscellaneous

Outstanding Shares
14,821,000
Free Float
14,287,000
Market Cap
$7.46 million
Optionable
Not Optionable
Beta
1.98
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Roni Mamluk M.D. (Age 55)
    Ph.D., Pres, CEO & Director
    Comp: $692.06k
  • Mr. Yossi Maimon CPA (Age 51)
    CPA, M.B.A., MBA, CFO, Sec. & Treasurer
    Comp: $556.43k
  • Dr. Gary B. Gordon M.D. (Age 69)
    Ph.D., Chief Medical Officer
    Comp: $577.4k
  • Dr. Shmuel Tuvia Ph.D.
    Chief Scientific Officer
  • Ms. Irit Klipper Avni M.A.
    VP of HR
  • Ms. Dana Gelbaum M.B.A. (Age 48)
    M.Sc., Chief Bus. Officer

Key Competitors

View All Competitors













AYLA Stock - Frequently Asked Questions

Should I buy or sell Ayala Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" AYLA shares.
View AYLA analyst ratings or view top-rated stocks.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) released its earnings results on Monday, November, 15th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.12. The business had revenue of $0.63 million for the quarter, compared to the consensus estimate of $0.82 million. Ayala Pharmaceuticals had a negative trailing twelve-month return on equity of 182.13% and a negative net margin of 2,341.69%.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Moderna (MRNA), CrowdStrike (CRWD), Dynavax Technologies (DVAX), Block (SQ), Abbott Laboratories (ABT), Alpine Immune Sciences (ALPN), Advanced Micro Devices (AMD), BioLineRx (BLRX), Cognex (CGNX) and Micron Technology (MU).

When did Ayala Pharmaceuticals IPO?

(AYLA) raised $50 million in an initial public offering (IPO) on Friday, May 8th 2020. The company issued 3,300,000 shares at a price of $14.00-$16.50 per share. Citigroup and Jefferies served as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers.

What is Ayala Pharmaceuticals' stock symbol?

Ayala Pharmaceuticals trades on the NASDAQ under the ticker symbol "AYLA."

What is Ayala Pharmaceuticals' stock price today?

One share of AYLA stock can currently be purchased for approximately $0.50.

How much money does Ayala Pharmaceuticals make?

Ayala Pharmaceuticals (NASDAQ:AYLA) has a market capitalization of $7.46 million and generates $3.51 million in revenue each year. The company earns $-40,250,000.00 in net income (profit) each year or ($2.52) on an earnings per share basis.

How can I contact Ayala Pharmaceuticals?

Ayala Pharmaceuticals' mailing address is Oppenheimer 4, Rehovot L3, 7670104. The official website for the company is www.ayalapharma.com. The company can be reached via phone at 857-444-0553 or via email at ir@ayalapharma.com.

This page (NASDAQ:AYLA) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -